InsidersTradesSigma
Canopy Growth Corp Stock: price and insider trades · United States · SEC (Form 4)
Track the Canopy Growth Corp share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Food & Agriculture sector, Canopy Growth Corp has logged 128 public disclosures. Market capitalisation: €448.4m. The latest transaction was filed on 29 June 2026 (Cession). Among the most active insiders: Lazzarato David Angelo. All data is free.
128
Insider Decl.
0
Thresholds
€42,364
1 ops.
Buy Volume
€1m
48 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Canopy Growth Corp Hold (neutral), based on 1 analysts. Average price target: US$1.22.
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 25,180 of 25,791 companies
10.7
score / 100
Value8
Quality13
FCF yld-16%
Earn yld-61%
EV/EBITDA·
ROE-45%
Gross mgn24%
Net mgn-92%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 June 2026
Declarations128 total
3,197 sharesCommon SharesSEC:0001104659-26-078837:0
3,197 sharesCommon SharesSEC:0001104659-26-078842:0
22,674 sharesCommon SharesSEC:0001104659-26-078832:0
15,054 sharesCommon SharesSEC:0001104659-26-078840:0
108,324 sharesCommon SharesSEC:0001104659-26-076419:0
108,324 sharesCommon SharesSEC:0001104659-26-076415:0
1,056,152 sharesCommon SharesSEC:0001104659-26-076407:0
135,231 sharesCommon SharesSEC:0001104659-26-076407:1
396,012 sharesCommon SharesSEC:0001104659-26-076410:0
58,994 sharesCommon SharesSEC:0001104659-26-076410:1
379,018 sharesCommon SharesSEC:0001104659-26-076411:0
9,285 sharesCommon SharesSEC:0001104659-26-076411:1
108,324 sharesCommon SharesSEC:0001104659-26-076413:0
162,485 sharesCommon SharesSEC:0001104659-26-076417:0
2,216 shares@ US$1.58100.0% of flowCommon SharesSEC:0001104659-25-095030:0
10,451 shares@ US$1.5833.6% of flowCommon SharesSEC:0001104659-25-095025:0
10,408 shares@ US$1.586.1% of flowCommon SharesSEC:0001104659-25-095029:0
15,677 shares@ US$1.588.4% of flowCommon SharesSEC:0001104659-25-095031:0
27,469 shares@ US$1.8261.9% of flowCommon SharesSEC:0001104659-25-092515:0
Ideal exit: 19 Jun 2026 (T+270)
2,012 shares@ US$0.924.1% of flowCommon SharesSEC:0001104659-25-031153:0
3,004 shares@ US$0.921.0% of flowCommon SharesSEC:0001104659-25-031163:0
2,004 shares@ US$0.920.7% of flowCommon SharesSEC:0001104659-25-031167:0
50,000 shares0Common SharesSEC:0001104659-25-013003:0
3,006 shares@ US$2.673.1% of flowCommon SharesSEC:0001104659-25-000800:0
1,996 shares@ US$2.672.2% of flowCommon SharesSEC:0001104659-25-000804:0
25 of 128 declarations
About Canopy Growth Corp
Canopy Growth Corp. (ticker CGC) is a Canadian cannabis company listed in the United States on the Nasdaq market, with its corporate headquarters in Smiths Falls, Ontario, Canada. For French-speaking investors, it is one of the best-known names in the global cannabis industry, positioned at the intersection of medical cannabis, adult-use cannabis, and consumer products. The company emerged in the 2010s as Canada moved toward legalization and then expanded through a mix of brand building, acquisitions, and international licensing. Canopy Growth’s business model is now organized around several complementary revenue streams. In Canada, it sells medical cannabis and, to a lesser extent, adult-use cannabis. Internationally, it serves medical patients in markets including Europe and Australia, with management highlighting activity in Germany, Poland, and Australia. Another important pillar is Storz & Bickel, the company’s vaporization-device business, which gives Canopy a more industrial, hardware-oriented exposure and a premium product platform. Its brand portfolio includes Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, alongside Storz & Bickel’s category-defining vaporization devices. From a competitive standpoint, Canopy Growth remains one of the most recognized cannabis companies in North America, but it is also a company in transition. The strategic emphasis has shifted toward simplifying the operating footprint, improving profitability, and strengthening the balance sheet. That matters because the cannabis sector has remained highly competitive, regulation-driven, and financially demanding. Canopy’s brand strength and global medical reach are meaningful assets, but the company must continue to manage pricing pressure, uneven consumer demand, and regulatory complexity across jurisdictions. Recent developments reinforce that balance-sheet repair and execution are the key investment themes. In 2025 and early 2026, Canopy Growth announced recapitalization steps, debt prepayments, and a new at-the-market equity program of up to US$200 million to enhance liquidity and financial flexibility. Its fiscal 2025 results showed improved Adjusted EBITDA and continued cost discipline, while management emphasized the integration of its medical cannabis operations into a single global platform. The company also reported that German medical cannabis performance benefited from a broader patient product portfolio. Overall, CGC remains a Nasdaq-listed cannabis exposure with recognizable brands and international reach, but the investment case is still centered on restructuring progress, margin recovery, and balance-sheet strength in the United States-listed capital market context.
